BRC-001

BRC-001 is a proprietary, botanically derived cannabinoid therapeutic developed as a high cannabidiol (CBD) plant extract. It is formulated with other cannabinoids in targeted ratios and is being investigated for its potential to treat joint pain (arthralgia) associated with aromatase inhibitor therapy in postmenopausal women with estrogen receptor-positive breast cancer. The mechanism of action is believed to involve modulation of the endocannabinoid system through cannabidiol and potentially other cannabinoids, aiming to provide analgesic effects and improve quality of life for patients experiencing aromatase inhibitor-induced arthralgia. BRC-001 represents an experimental supportive care therapy designed as an alternative to opiates for pain relief and benzodiazepines for anxiety or insomnia in this patient population[1][2][3][4][5].

Other names

High Cannabidiol Plant Extracthigh CBD plant extract